[Federal Register Volume 73, Number 164 (Friday, August 22, 2008)]
[Notices]
[Pages 49653-49654]
From the Federal Register Online via the Government Publishing Office [www.gpo.gov]
[FR Doc No: E8-19503]


-----------------------------------------------------------------------

DEPARTMENT OF DEFENSE

Office of the Secretary


Meeting of the Uniform Formulary Beneficiary Advisory Panel

AGENCY: Department of Defense, Assistant Secretary of Defense (Health 
Affairs).

ACTION: Notice of meeting.

-----------------------------------------------------------------------

SUMMARY: Under the provisions of the Federal Advisory Committee Act of 
1972 (5 U.S.C., Appendix, as amended) and the Sunshine in the 
Government Act of 1976 (U.S.C. 552b, as amended) the Department of 
Defense announces the following Federal Advisory Committee Meeting of 
the Uniform

[[Page 49654]]

Formulary Beneficiary Advisory Panel (hereafter referred to as the 
Panel).

DATES: September 17, 2008 (8 a.m. to 4 p.m.)

ADDRESSES: Naval Heritage Center Theater, 701 Pennsylvania Avenue, NW., 
Washington, DC 20004.

FOR FURTHER INFORMATION CONTACT: LtCol Thomas Bacon, Designated Federal 
Officer, Uniform Formulary Beneficiary Advisory Panel, Skyline 5, Suite 
810, 5111 Leesburg Pike, Falls Church, Virginia 22041-3206, Telephone: 
(703) 681-2890, Fax: (703) 681-1940, e-mail address: 
<a href="/cdn-cgi/l/email-protection#73111203011602061600070033071e125d1c00175d1e1a1f"><span class="__cf_email__" data-cfemail="42202332302733372731363102362f236c2d31266c2f2b2e">[email protected]</span></a>.

SUPPLEMENTARY INFORMATION:
    Purpose of Meeting: The Panel will review and comment on 
recommendations made to the Director, TRICARE Management Activity, by 
the Pharmacy and Therapeutics (P&T) Committee regarding the Uniform 
Formulary.
    Meeting Agenda: Sign-In; Welcome and Opening Remarks; Public 
Citizen Comments; Scheduled Therapeutic Class Reviews--Self-Monitoring 
Blood Glucose Systems (meters and strips); Overactive Bladder Agents; 
Designated Newly Approved Drugs; Panel Discussions and Vote, and 
comments following each therapeutic class review.
    Meeting Accessibility: Pursuant to 5 U.S.C. 552b, as amended, and 
41 CFR 102-3.140 through 102-3.165, and the availability of space this 
meeting is open to the public. Seating is limited and will be provided 
only to the first 220 people signing in. All persons must sign in 
legibly.
    Pursuant to 5 U.S.C. 552b, as amended, and 41 CFR 102-3.155, the 
Department of Defense has determined that the Administrative Work 
Meeting (to be held prior to the public meeting) shall be closed to the 
public. The Under Secretary of Defense (Personnel and Readiness), in 
consultation with the Office of the DoD General Counsel, has determined 
in writing that the public interest requires that all or part of this 
meeting be closed to the public because they will be concerned with 
matters listed in Section 552b(c)(1) of title 5, United States Code.
    Prior to the public meeting the Panel will conduct an 
Administrative Work Meeting from 7 a.m. to 7:50 a.m. to discuss 
administrative matters of the Panel. The Administrative Work Meeting 
will be held at the Naval Heritage Center Conference Room, 701 
Pennsylvania Avenue, NW., Washington D.C. 20004. Pursuant to 41 CFR 
102-3.160, the Administrative Work Meeting will be closed to the 
public.
    Written Statements: Pursuant to 41 CFR 102-3.105(j) and 102-3.140, 
the public or interested organizations may submit written statements to 
the membership of the Panel at any time or in response to the stated 
agenda of a planned meeting. Written statements should be submitted to 
the Panel's Designated Federal Officer; the Designated Federal 
Officer's contact information can be obtained from the GSA's FACA 
Database--https://www.fido.gov/facadatabase/public.asp.
    Written statements that do not pertain to the scheduled meeting of 
the Panel may be submitted at any time. However, if individual comments 
pertain to a specific topic being discussed at a planned meeting then 
these statements must be submitted no later than five (5) business days 
prior to the meeting in question. The Designated Federal Officer will 
review all submitted written statements and provide copies to all the 
committee members.
    Oral Public Comments: In addition to written statements, the Panel 
will set aside one (1) hour for individuals or interested groups to 
address the Panel. To ensure consideration of their comments, 
individuals and interested groups should submit written statements as 
outlined in this notice, but if they still want to address the Panel 
then they will be afforded the opportunity to register to address the 
Panel. The Panel's Designated Federal Officer will have a ``Sign Up 
Roster'' available at the Panel meeting for registration on a first-
come, first-serve basis. Those wishing to address the Panel will be 
given no more than five (5) minutes to present their comments, and at 
the end of the one (1) hour time period no further public comments will 
be accepted. Anyone who signs up to address the Panel but is unable to 
do so due to the time limitation may submit their comments in writing; 
however, they must understand that their written comments may not be 
reviewed prior to the Panel's deliberation. Accordingly, the Panel 
recommends that individuals and interested groups consider submitting 
written statements instead of addressing the Panel.

    Dated: August 15, 2008.
Patricia L. Toppings,
OSD Federal Register Liaison Officer, Department of Defense.
 [FR Doc. E8-19503 Filed 8-21-08; 8:45 am]
BILLING CODE 5001-06-P


</pre><script data-cfasync="false" src="/cdn-cgi/scripts/5c5dd728/cloudflare-static/email-decode.min.js"></script></body>
</html>